Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0459 • ACR Convergence 2023
Upadacitinib Monotherapy versus Methotrexate in Patients with Rheumatoid Arthritis: Efficacy and Safety Through 5 Years in the SELECT-EARLY Randomized Controlled Trial
Ronald van Vollenhoven¹, Vibeke Strand², Tsutomu Takeuchi³, Nilmo Chávez⁴, Pablo Mannucci Walter⁵, Attul Singhal⁶, Jerzy Swierkot⁷, Nasser Khan⁸, Xianwei Bu⁹, Yihan Li⁹, Sara Penn⁹, Heidi Camp⁹ and Jacob Aelion¹⁰, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Stanford University, Portola Valley, CA, ³Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁴Instituto Guatemalteco de Seguridad Social, Guatemala, Guatemala, ⁵Aprillus Asistencia e Investigación, Buenos Aires, Argentina, ⁶Southwest Rheumatology Research Group, Dallas, TX, ⁷Department of Rheumatology and Internal Medicine, Wrocław Medical Hospital, Wrocław, Poland, ⁸Pharmacovigilance and Patient Safety, AbbVie, Inc., North Chicago, IL, ⁹AbbVie, Inc., North Chicago, IL, ¹⁰West Tennessee Research Institute, Jackson, TN
Background/Purpose: To evaluate the efficacy and safety of upadacitinib (UPA) monotherapy vs MTX monotherapy over 5 yrs among MTX-naïve patients with moderately to severely active…
Abstract Number: 0745 • ACR Convergence 2023
Artificial Intelligence Models for Computer-Assisted Joint Detection and Sharp-van Der Heijde Score Prediction in Hand Radiographs from Patients with Rheumatoid Arthritis
Carol Hitchon¹, Saqib Al Islam¹, Daryl LX Fung¹, Qian Liu¹, Leann Lac¹, Susan Bartlett², Louis Bessette³, Gilles Boire⁴, Vivian Bykerk⁵, Glen Hazlewood⁶, Edward Keystone⁷, Janet Pope⁸, Orit Schieir⁹, Carter Thorne¹⁰, Diane Tin¹¹, Marie-France Valois¹², Désirée van der Heijde¹³, Canadian Early Arthritis Cohort (CATCH) Investigators¹⁴, Liam O'Neil¹ and Pingzhao Hu¹⁵, ¹University of Manitoba, Winnipeg, MB, Canada, ²McGill University, Montreal, QC, Canada, ³Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁴Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵Hospital for Special Surgery, New York, NY, ⁶University of Calgary, Calgary, AB, Canada, ⁷Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹McGill University, Montréal, QC, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹The Arthritis Program Research Group, Newmarket, ON, Canada, ¹²McGill University, Pointe-Claire, QC, Canada, ¹³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ¹⁴CATCH, Winnipeg, MB, Canada, ¹⁵Western University, London, ON, Canada
Background/Purpose: Radiographs are used to detect and monitor joint damage due to rheumatoid arthritis (RA).Scoring methods such as the Sharp van der Heijde tool (SVH)…
Abstract Number: 0806 • ACR Convergence 2023
Effectiveness of a Technology-enabled Self-monitoring and Physical Therapist Counselling Program for Improving Self-management Ability in People with Rheumatoid Arthritis: A Randomized Controlled Trial
Linda Li¹, Hui Xie², Lynne feehan¹, Na Lu³, Alison Hoens⁴, Kelly English⁵, Eileen Davidson⁵, Catherine L. Backman⁶, Smruthi Ramachandran¹, Ellen Wang¹, Stephanie Therrien³, Julia Mucha¹, Teresa Liu-Ambrose¹, Kimberly Miller⁷, Christopher Shaw⁸ and Diane Lacaille⁹, ¹University of British Columbia, Vancouver, BC, Canada, ²Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Patient Advisory Board, Arthritis Research Canada, Vancouver, BC, Canada, ⁶The University of British Columbia, Vancouver, BC, Canada, ⁷BC Children’s and Women’s Hospital & Health Centre, Vancouver, BC, Canada, ⁸Simon Fraser University, Burnaby, BC, Canada, ⁹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: To achieve optimal health outcomes, people with rheumatoid arthritis (RA) need to know their symptom patterns and be able to practice self-care activities. With…
Abstract Number: 0973 • ACR Convergence 2023
Real-World Comparative Effectiveness Study of Janus Kinase Inhibitors Compared to Biologic Disease Modifying Antirheumatic Drugs in Korean Patients with Rheumatoid Arthritis
Soo-Kyung Cho¹, Yeo-Jin Song¹, Jungyong Han², Hye Won Kim³, Eunwoo Nam³, Sang Won Lee⁴, Shin-Seok Lee⁵, Hye-Soon Lee⁶, Sung-Hoon Park⁷, Yeon-Ah Lee⁸, Sung Hae Chang⁹, Min-Chan Park¹⁰, Hyoun-Ah Kim¹¹, Hyun-Sook Kim¹², Bo Young Yoon¹³, Yong-Gil Kim¹⁴, Hae-Rim Kim¹⁵, Jae Hoon Kim¹⁶, Jisoo Lee¹⁷, Jeongim Choi¹⁸, Wan-Sik Uhm¹⁹ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Hanyang University Institute for Rheumatology Research, Seoul, South Korea, ⁴Hanyang University, Seoul, South Korea, ⁵Chonnam National University Medical School & Hospital, Gwangju, South Korea, ⁶Hanyang University, Guri, South Korea, ⁷Daegu Catholic University School of Medicine, Daegu, South Korea, ⁸Kyung Hee University Hospital, Seoul, South Korea, ⁹Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, South Korea, ¹⁰Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, ¹¹Ajou University School of Medicine, Suwon, South Korea, ¹²Soonchunhyang University Seoul Hospital, Seoul, South Korea, ¹³Inje University Ilsan Paik Hospital, Goyang, South Korea, ¹⁴Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea, ¹⁵Rheumatology, Konkuk University Medical Center, Seoul, South Korea, ¹⁶Korea University Medical Center, Seoul, South Korea, ¹⁷Ewha Womans Univ College of Medicine, Seoul, South Korea, ¹⁸Busan Saint Mary's Hospital, Busan, South Korea, ¹⁹Uhm's Rheumatism Clinic, Seoul, South Korea
Background/Purpose: Although clinical trials have shown similar effectiveness between Janus kinase inhibitors (JAKi) and biologic disease-modifying anti-rheumatic drugs (bDMARDs), the choice between these two options…
Abstract Number: 1015 • ACR Convergence 2023
Health Care Access in an Indigenous North American Population of Rheumatoid Arthritis Patients and Their At-risk First-Degree Relatives
Dana Wiens¹, David Robinson¹, Irene Smolik¹, Cheryl Barnabe², Hani El-Gabalawy¹ and Liam O'Neil¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²University of Calgary, Calgary, AB, Canada
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic autoimmune disease that requires access to subspecialty care. Although Canada has a universal healthcare system, there are complex…
Abstract Number: 1257 • ACR Convergence 2023
The Psychological Experience of Work for People with Inflammatory Arthritis (IA)
Joan Westreich¹, Adena Batterman¹, Anna Balakrishnan¹, Roberta Horton¹, Minerva Nong¹, Vivian Bykerk² and Theodore Fields¹, ¹Hospital for Special Surgery, New York, NY, ²Department of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: A large body of research reports that people with inflammatory arthritis (IA) are at increased risk for work disability, which profoundly affects all aspects…
Abstract Number: 1276 • ACR Convergence 2023
Multimorbidity Burden Predicts Lower Likelihood of Remission in Patients with Rheumatoid Arthritis
Cynthia Crowson, Chanakya Kodishala, Tina Gunderson, Atkinson Elizabeth, Vanessa Kronzer, John Davis, Courtney Arment, Delamo Bekele, Thomas Mason, Lynne Peterson, Kerry Wright and Elena Myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Seropositivity has historically been associated with poor disease outcomes in patients with rheumatoid arthritis (RA). Seronegative RA is on the rise and is associated…
Abstract Number: 1292 • ACR Convergence 2023
Active Rheumatoid Arthritis Patients Exhibit an Altered Serum Lipidomic Profile Directly Linked to Disease Activity, Which Is Reversed by Biologic and Targeted Synthetic DMARD
Chary Lopez-Pedrera¹, Laura Muñoz-Barrera², Beatriz Vellón², Rocio Guzman², Tomás Cerdó², Rafaela Ortega Castro³, Jerusalem Calvo⁴, Mª Angeles Aguirre⁵, Pedro Segui², Ivan Arias de la Rosa⁶, Maria del Carmen Abalos-Aguilera⁷, Desiree Ruiz-Vilchez², Christian Merlo-Ruiz², Jose Javier Perez-Venegas⁸, Javier Godoy⁹, Dolores Ruiz-Montesinos¹⁰, Carmen Dominguez⁸, Carlos Rodriguez-Escalera¹¹, Carmen Romero-Barco¹², Antonio Fernandez-Nebro¹², Natalia Mena Vazquez¹³, Julia Uceda Montañez¹⁴, Charo Santos¹⁴, Nuria Barbarroja¹⁵, Eduardo Collantes Estévez¹⁶, Mª del Mar Malagon², Alejandro Escudero Contreras⁴ and Carlos Perez-Sanchez¹⁷, ¹IMIBIC - Reina Sofia Hospital, Córdoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ³Hospital Reina Sofía, Cordoba, Spain, ⁴Reina Sofia University Hospital, Córdoba, Spain, ⁵Reina Sofía University Hospital/ Rheumatology Department, Córdoba, Spain, ⁶IMIBIC/Reina Sofia Hospital/University of Cordoba. Rheumatology service. Cordoba. Spain, Cordoba, Spain, ⁷Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁸Virgen Macarena University Hospital, Sevilla, Spain, ⁹Jaen University Hospital, Jaen, Spain, ¹⁰Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹¹Virgen de la Victoria Hospital, Malaga, Spain, ¹²Hospital Regional Universitario de Málaga, Malaga, Spain, ¹³IBIMA, Málaga, Spain, ¹⁴Hospital Virgen de Valme, Sevilla, Spain, ¹⁵University of Cordoba, Córdoba, Spain, ¹⁶Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Cordoba, Spain, ¹⁷IMIBIC, Córdoba, Spain
Background/Purpose: Lipid metabolism impacts immune cell plasticity, activation, differentiation, and function, making the analysis of the lipidomic profile crucial in understanding chronic inflammatory diseases like…
Abstract Number: 1308 • ACR Convergence 2023
Certolizumab Pegol Shows Longer Retention Rate in Comparison with Other TNF Inhibitors in Patients with Rheumatoid Arthritis and High Rheumatoid Factor Titers at Baseline. a Multicentre and Retrospective Study
Clementina López Medina¹, Jerusalem Calvo², Maria del Carmen Abalos-Aguilera³, Francisco Cepas⁴, Chamaida Plasencia-Rodríguez⁵, Ana Martinez Feito⁶, Alejandro Balsa⁵, Regina Faré-García⁷, Antonio Juan Mas⁷, Virginia Ruiz-Esquide⁸, Luis Sainz-Comas⁹, César Díaz-Torné⁹, Javier Godoy¹⁰, Isabel Anon Onate¹¹, Natalia Mena Vazquez¹², SARA MANRIQUE¹³, Marina soledad Moreno Garcia¹⁴, Rafaela Ortega Castro¹⁵ and Alejandro Escudero-Contreras¹⁶, ¹Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris; Rheumatology Department, Reina Sofia Hospital, Cordoba / IMIBIC / University of Cordoba, Cordoba, Spain, ²Reina Sofia University Hospital, Córdoba, Spain, ³Rheumatology Department, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Córdoba, Spain, ⁴Maimonides Institute for Biomedical Research (IMIBIC), Córdoba, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, ⁷Son Llazter University Hospital, Palma, Spain, ⁸Hospital Clinic, Rheumatology, Barcelona, Spain, ⁹Hospital de Santa Creu i Sant Pau, Barcelona, Spain, ¹⁰Jaen University Hospital, Jaen, Spain, ¹¹Hospital Universitario de Jaen, Jaen, Spain, ¹²IBIMA, Málaga, Spain, ¹³Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ¹⁴Hospital Miguel Servet, Zaragoza, Spain, ¹⁵Hospital Reina Sofía, Cordoba, Spain, ¹⁶Rheumatology Department, Reina Sofia University Hospital, Cordoba/Maimonides Biomedical Research Institute of Cordoba (IMIBIC)/University of Cordoba, Córdoba, Spain
Background/Purpose: Rheumatoid Factor (RF) is an antibody against the Fc fragment of IgG that contributes to the Rheumatoid Arthritis (RA) development. RF can bind the…
Abstract Number: 1325 • ACR Convergence 2023
Integrated Safety Analysis of Filgotinib in Patients with Moderate to Severe Active Rheumatoid Arthritis with a Maximum Exposure of 8.3 Years
Kevin Withrop¹, Daniel Aletaha², Roberto F. Caporali³, Yoshiya Tanaka⁴, Tsutomu Takeuchi⁵, Paul Van Hoek⁶, Pieter-Jan Stiers⁷, Vijay Rajendran⁸, Katrien Van Beneden⁶, Jacques-Eric Gottenberg⁹ and Gerd Burmester¹⁰, ¹Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ²Division of Rheumatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria, Wien, Austria, ³Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ⁴University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁶Medical Safety, Galapagos NV, Mechelen, Belgium, ⁷Biostatistics, Galapagos NV, Mechelen, Belgium, ⁸Clinical Research, Galapagos NV, Mechelen, Belgium, ⁹Rheumatology Department, Strasbourg University Hospital, Strasbourg, France, ¹⁰Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose: Filgotinib (FIL) is an oral Janus kinase 1 preferential inhibitor, approved for the treatment of moderate to severe active rheumatoid arthritis (RA). In previous…
Abstract Number: 1341 • ACR Convergence 2023
Impact of Ultrasound on Physician Assessments of Patients with RA with Elevated Clinical Disease Activity Scores
Stephanie Song¹, Odette Kolenky¹, Antje Greenfield², Dana Direnzo³, Joshua Baker⁴ and Michael George⁴, ¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania Health System, Philadelphia, PA, ³University of Pennsylvania, Bala Cynwyd, PA, ⁴University of Pennsylvania, Philadelphia, PA
Background/Purpose: Treat-to-target is recommended in RA, but physicians often do not escalate therapy despite elevated disease activity measures due to uncertainty regarding the true degree…
Abstract Number: 1630 • ACR Convergence 2023
Patient-Reported Fatigue Associated with Joint Histopathology in Rheumatoid Arthritis
Diyu Fisher¹, Dana Orange², Melanie Smith³, Bella Mehta⁴, Edoardo Spolaore⁵, Edward DiCarlo³, Dongmei Sun³, Laura Donlin³ and Susan Goodman³, ¹Stony Brook Medicine, Port Jefferson Station, NY, ²The Rockefeller University, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵HSS, New York, NY
Background/Purpose: Fatigue or tiredness is an important symptom for patients with rheumatoid arthritis (RA), yet the factors associated with fatigue are poorly understood and may…
Abstract Number: 1725 • ACR Convergence 2023
Distinct Perivascular and Intravascular Lymphatic Mast Cells and Their Role in Lymphatic Clearance, Joint Inflammation, and Bone Erosion in the TNF-Transgenic Murine Arthritis Model
Yue Peng¹, H. Mark Kenney², Karen Bentley³, Lianping Xing⁴, Christopher T Ritchlin⁵ and Edward Schwarz³, ¹University of Rochester Medical Center, Rochester, NY, ²University of Rochester School of Medicine and Dentistry, Henrietta, NY, ³University of Rochester, Rochester, NY, ⁴University of Rochester Medical Center, Webster, NY, ⁵University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY
Background/Purpose: Inflammatory-erosive arthritis is exacerbated by lymphatic dysfunction (1), and mast cells (MCs) regulate lymphatic vessel contractions via release of inflammatory and vasoactive mediators (2).…
Abstract Number: 1742 • ACR Convergence 2023
Sputum Citrullinated Proteins and Sputum Anti-Cit-S100A8/A9 IgG Antibodies Are Increased in Serum Anti-CCP-IgG Positive Individuals Who Developed RA
Rachna Talluri¹, Sudeshna Sen², Timothy Wilson³, Adam Savage⁴, Mark Gillespie⁴, Tom Bumol⁴, Marie Feser¹, Jill Norri⁵, Michael Holer¹, kevin Deane¹, Paul Thompson² and Kristen Demoruelle¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO, ²University of Massachusetts Chan Medical School, Worcester, MA, ³Thomas Jefferson University, Philadelphia, PA, ⁴Allen Institute for Immunology, Seattle, WA, ⁵Colorado School of Public Health, Denver, CO
Background/Purpose: The presence of anti-CCP-IgG in the blood identifies individuals who are "at-risk" of developing RA. Our group has reported that in a cohort of…
Abstract Number: 1758 • ACR Convergence 2023
Identification of Circulating Autoantibodies Associated with ACPA Status in Early Rheumatoid Arthritis
Lucía Lourido¹, Vijay Joshua², Monika Hansson³, Ronald Sjöberg⁴, Elisa Pin⁴, Cristina Ruiz-Romero⁵, Peter Nilsson⁴, Lars Klareskog² and Francisco J. Blanco⁶, ¹Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, Spain, ²Karolinska Institutet, Stockholm, Sweden, ³Division for Rheumatology, Department of Medicine (Solna) Karolinska Institutet, Stockholm, Sweden, ⁴Department of Protein Science, SciLifelab, KTH Royal Institute of Technology, Stockholm, Sweden, ⁵1) Unidad de Proteómica. Grupo de Investigación de Reumatología (GIR). Instituto de Investigación Biomédica de A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). C/ As Xubias de Arriba 84, 15006, A Coruña, España. 4) Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN). Av. Monforte de Lemos, 3-5. Pabellón 11,28029, Madrid, Spain, ⁶Rheumatology department, Complexo Hospitalario Universitario A Coruña (CHUAC). Instituto de Investigación Biomédica A Coruña (INIBIC), A Coruña, Spain
Background/Purpose: Rheumatoid arthritis (RA) is associated with the presence of autoantibodies being the anti-citrullinated protein antibodies (ACPAs) the hallmark as they are present in almost…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].